Brief: Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Oculis Holding AG

28/02/2024 11:34

Feb 28 (Reuters) - Oculis Holding AG  CR5.F :
    * OCULIS PROVIDES UPDATES AT RESEARCH AND DEVELOPMENT DAY ON
LATE-STAGE CLINICAL TRIALS AND ANNOUNCES KEY LEADERSHIP
APPOINTMENTS
    * OCULIS HOLDING AG - COMPLETED ENROLLMENT IN PHASE 2B
RELIEF
TRIAL OF LICAMINLIMAB, ANTI-TNF (TUMOR NECROSIS FACTOR) ALPHA
EYE DROPS IN DRY EYE DISEASE
    * OCULIS HOLDING AG - SECOND PHASE 3 TRIAL (DIAMOND-2) OF
OCS-01
EYE DROPS IN DIABETIC MACULAR EDEMA (DME) INITIATED AS PLANNED

Source text for Eikon:  ID:nGNXbCg6qM 
Further company coverage:  CR5.F 

 ((Reuters.Briefs@thomsonreuters.com;))